Views
2 years ago

125 - SA Muñoz, A Mejías Delamano, J Molina, HA Serra - Abril 2021

  • Text
  • Sciens
  • Serra
  • Molina
  • Delamano
  • Nota
  • Tabla
  • Editorial
  • Especialista
  • Duloxetina
  • Dosis
  • Gabapentin
  • Pregabalina
  • Neuropathic
  • Tratamiento
  • Dolor
Estado actual del tratamiento del dolor neuropático

Dr. Santiago Alfredo

Dr. Santiago Alfredo Muñoz, Dr. Alexis Mejías Delamano, Dr. Jonathan Molina, Dr. Héctor Alejandro Serra Referencias bibliográficas • 1. Part III: Pain Terms, A Current List with Definitions and Notes on Usage” (pp 209-214) Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy, edited by H. Merskey and N. Bogduk, IASP Press, Seattle, ©1994. • 2. Harrison, Kasper, Braunwald, et al. Principios de Medicina Interna. McGraw Hill-Interamericana. Año 2006, 16° edición. • 3. Finnerup NB, Kuner R and Jensen T. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021, 101(1): 259-301. • 4. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016, 157: 1382-86. • 5. Machelska, Celik MO. Recent advances in understanding neuropathic pain: glia, sex differences and epigenetics. F1000Research. 2016, 5: 2743. • 6. Doth AH, Hansson PT, Jensen M, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010; 149(2):338–44. • 7. Meyer-Rosberg K, Burckhardt CS, Huizar K, et al. A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain. 2001; 5(4):391– 403. • 8. Smith BH, Torrance N, Bennett M, et al. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain. 2007; 23(2):143–9. • 9. Dermanovic D, Hrabac P, Skegro D, et al. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes. 2014; 12(1):171. • 10. Inoue S, Taguchi T, Yamashita T, et al. The prevalence and impact of chronic neuropathic pain on daily and social life: A nationwide study in a Japanese population. Eur J Pain. 2017; 21(4): 727–37. • 11. Aloisi AM, Berlincioni V, Torta R, et al. The role of gender, psycho-social factors and anthropological-cultural dimensions on pain in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Eur J Phys Rehabil Med. 2016; 52(5):730–40. • 12. Galer BS, Gianas A and Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000, 47, 123-28. • 13. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2):162–73. • 14. GerardoCorrea-Illanes. Neuropathic pain, clasification and management for general practicioners. Revista Médica Clínica Las Condes. 2014, 25(2): 189-99. • 15. Snyder Matthew, Gibbs Lawrence and Lindsay Tammy. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016, 94: 227-34. • 16. Szok Délia, Tajti János, Nyári Aliz, et al. Therapeutic approaches for peripheral and central Neuropathic Pain. Behavioural Neurology. 2019, 1-13. • 17. Lombardo Leo and Wallace Mark. Assessment and treatment of Neuropathic Pain. Practical Pain Management. 13(8): • 18. Bates D, Schultheis C, Hanes M, et al. A comprehensive algorithm for management of neuropathic pain. Pain Medicine. 2019, 20: S2-S12. • 19. Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Revue Neurologique. 2019, 175: 46-50. • 20. Liampas Andreas, Rekatsina Martina, Vadalouca Athina, et al. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2020. • 21. Mazzoglio MJ, Mejías Delamano A, Muñoz S, et al. Psicofarmacología en esquema para el equipo interdisciplinario de salud mental. Editorial Impresiones Buenos Aires. 2016. Segunda edición. • 22. Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor α2γ1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009, 139: 380-92. • 23. Sheena Derry S, Rice A, Cole P, et al. Capsaicina tópica (alta concentración) para el dolor neuropático crónico en adultos. Cochrane Database of Systematic Reviews. 2017. • 24. Parra Soto CE, Miñana Barrios M, Jimenez Salas B, et al. Tratamiento del dolor neuropático localizado postquirúrgico con parche de capsaicina al 8%. Ocronos. 2020, Vol. III. Nº 5. • 25. National Institute for Health and Care Excellence (NICE). Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013. • 26. Cavalli Eugenio, Mammana Santa, Nicoletti Ferdinando, et al. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. International Journal of Immunopathology and Pharmacology. 2019, 33: 1-10. • 27. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology. 2010, 17: 1113-23. • 28. Schlereth Tanja. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology. Neurological Research and Practice. 2020, 2: 16. • 29. Acevedo JC, Amaya A, León Casasola O, et al. Guidelines for the diagnosis and management of Neuropathic Pain: Consensus of a Group of Latin American Experts. Journal of Pain and Palliative Care Pharmacotherapy. 2009, 23(3): 261-81. • 30. SED-SEMERGEN-SemFYC-SEMG. Guía de Práctica Clínica sobre el tratamiento farmacológico del Dolor Neuropático Periférico en Atención Primaria. Masterline División editorial. Año 2016. • 31. IASP. NeuPSIG (Neuropathic Pain Special Interest Group). Pharmacological management of Neuropathic Pain. 2010, vol XVIII, issue 9. • 32. American Society of Anesthesiologists Task Force and American Society of Regional Anesthesia and Pain Medicine. Practice Guidelines for Chronic Pain Management. Anesthesiology. 2010, 112: 1-1. • 33. Management of Neuropathic Pain for Adults in Primary Care. National Health Services (NHS), United Kingdom. 2018 • 34. Pop-Busui Rodica, Boulton Andrew, Fledman Eva, et al. Diabetic Neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017, 40: 136-154. • 35. Bril V, England J, Franklin G, et al. Evidence-based guideline: treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation. Neurology.2011, 1758-65. • 36. Dworkin R, Johnson R, Breuer J, et al. Recommendations for the management of Herpes Zoster. Clinical Infectious Diseases. 2007, 44: S1-26. • 37. Kamerman PR, Finnerup NB, De Lima L, Haroutounian S, Raja SN, Rice ASC, Smith BH, Treede RD. Gabapentin for neuropathic pain: An application to the 21st meeting of the WHO Expert Committee on Selection and Use of Essential Medicines for the inclusion of gabapentin on the WHO Model List of Essential Medicines. DOI:10.6084/m9.figshare.3814206.v2, 2016. 30 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015